Judge tells FTC and Impax to connect witness testimony to exhibits

The Federal Trade Commission’s administrative law judge on Thursday declined to rule on whether some exhibits were admissible during a pretrial hearing between the agency and generic drugmaker Impax Laboratories, who is accused for participating in a pay-for-delay scheme with brand name drug company Endo.

Unlock unlimited access to all Global Competition Review content